论文部分内容阅读
目的观察和探讨吉西他滨联合顺铂(GP)及放疗治疗局部晚期鼻咽癌的近期疗效。方法将该院收治的经病理确证为局部晚期鼻咽癌的20例患者使用GP方案同步放化疗治疗,患者在放疗第一、五周给予吉西他滨800mg/m2和顺铂25mg/m2,静脉滴入。使用西门子直线加速器对患者进行常规照射,鼻咽部总放疗剂量为(70~72)Gy/(35~36)次,2Gy/次;颈部淋巴结的总放疗剂量为(60~70)Gy/(30~35)次,2Gy/次。治疗后对患者行肿瘤疗效评价,对其不良反应进行分析。结果 20例患者中,完全缓解8例,部分缓解9例,病情稳定3例,近期有效率达85%。患者出现的不良反应主要为皮肤反应、口腔黏膜反应、胃肠道反应和骨髓抑制。出现不良反应的患者有5例,占25%,其中皮肤反应2例,口腔黏膜反应、胃肠道反应和骨髓抑制各1例。结论 GP方案同步放化疗治疗局部晚期鼻咽癌的近期疗效显著,不良反应的发生率较低,患者可耐受,值得临床推广使用。
Objective To observe and explore the short-term efficacy of gemcitabine combined with cisplatin (GP) and radiotherapy in the treatment of locally advanced nasopharyngeal carcinoma. Methods Twenty patients with locally advanced nasopharyngeal carcinoma confirmed by pathology were treated with concurrent chemoradiotherapy with GP regimen. Gemcitabine 800 mg / m2 and cisplatin 25 mg / m2 were given in the first and fifth week after radiotherapy. . The total radiation dose in the nasopharynx was (70-72) Gy / (35-36) times and 2Gy / times using the Siemens linear accelerator. The total radiation dose in the cervical lymph nodes was (60-70) Gy / (30 ~ 35) times, 2Gy / times. Tumor patients after treatment efficacy evaluation, analysis of their adverse reactions. Results Of the 20 patients, complete remission in 8 cases, partial remission in 9 cases, stable condition in 3 cases, the recent effective rate was 85%. The main adverse reactions occurred in patients with skin reactions, oral mucosal reactions, gastrointestinal reactions and bone marrow suppression. There were 5 cases of adverse reactions, accounting for 25%, of which skin reactions in 2 cases, oral mucosal reactions, gastrointestinal reactions and bone marrow suppression in 1 case. Conclusion GP regimen concurrent chemoradiotherapy for the treatment of locally advanced nasopharyngeal carcinoma has a significant short-term effect, the incidence of adverse reactions is low, the patient is tolerable, worthy of clinical promotion and use.